Advanced gastric cancer

Immune-suppressing molecules such as PD-L1 can be co-opted by cancer cells to suppress the natural immune response to cancer. Upregulation...


Eli Lilly has announced that the FDA ( Food and Drug Administration ) has approved Cyramza ( Ramucirumab ) as...


Vascular endothelial growth factor ( VEGF ) and VEGF receptor-2 ( VEGFR-2 )-mediated signalling and angiogenesis can contribute to the...


The FDA ( Food and Drug Administration ) has approved Ramucirumab ( Cyramza ) in combination with Paclitaxel as a...


Vascular endothelial growth factor ( VEGF ) and VEGF receptor-2 ( VEGFR-2 )-mediated signalling and angiogenesis can contribute to the...


Data on the investigational use of Pembrolizumab ( Keytruda ), an anti-PD-1 agent, in PD-L1 positive, advanced gastric cancer were...


Data on the investigational use of Pembrolizumab ( Keytruda ), an anti-PD-1 agent, in PD-L1 positive, advanced urothelial cancer (...


Immune-suppressing molecules such as PD-L1 can be co-opted by cancer cells to suppress the natural immune response to cancer. Upregulation...


The FDA ( Food and Drug Administration ) has assigned Priority Review to the regulatory submission for Ramucirumab as a...


The results from the Phase III REGARD trial of Ramucirumab as a single agent in patients with advanced gastric cancer...


There are no agents specifically approved in the United States or European Union for advanced gastric cancer patients. Gastric cancer...


Long-term follow-up results ( median follow up of 20.3 months ) from the lung cancer cohort ( n=129 ) of...


Bristol-Myers Squibb has announced long-term follow-up results ( median follow up of 20.3 months ) from the lung cancer cohort...


Neuroendocrine tumors ( NETs ) comprise a heterogeneous family of neoplasms with a wide and complex spectrum of clinical behavior....